This company has been acquired
Cidara Therapeutics Gestione
Criteri Gestione verificati 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Jeff Stein
Amministratore delegato
US$6.0m
Compenso totale
| Percentuale dello stipendio del CEO | 10.35% |
| Mandato del CEO | 12yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 3.4yrs |
| Durata media del Consiglio di amministrazione | 5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook
Catalysts About Cidara Therapeutics Cidara Therapeutics develops drug Fc conjugates aimed at preventing and treating serious infectious diseases such as influenza. What are the underlying business or industry changes driving this perspective?Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential
Summary Cidara Therapeutics delivered a 1,165%+ return, driven by positive CD388 data and Merck's $221.50/share acquisition offer. CD388 achieved statistically significant prevention efficacy up to 76% in phase 2b, leading to FDA alignment for the single pivotal phase 3 ANCHOR trial. Phase 3 ANCHOR trial reached 6,000-patient enrollment; interim analysis is expected Q1 2026, with BLA submission contingent on success for this and subsequent Southern Hemisphere study start. I maintain a "Hold" rating as the Merck acquisition awaits HSR clearance, with regulatory and competitive risks remaining. Plus, no further upside as the acquisition is already announced. Read the full article on Seeking AlphaBullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Summary Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388’s safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA’s Fast Track designation. Interestingly, CDTX reduced its workforce by 30% to concentrate on CD388. This could very well pay off if they're successful with their 2025 trials. Overall, CDTX stock trades at a reasonable valuation, so I feel it’s fair to give it a speculative “Buy” rating as a bet on CD388 in 2025. Read the full article on Seeking AlphaCidara Therapeutics: The underestimated potential of CD388
CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.Cidara spikes on $11M milestone payment from partner Mundipharma
The shares of clinical-stage biotech Cidara Therapeutics (NASDAQ:CDTX) gained over 8% pre-market Tuesday after the company announced that British drugmaker Mundipharma paid $11.1M as a milestone payment under a 2019 licensing deal. The payment follows the acceptance of the marketing authorization application (MAA) for rezafungin by the European Medicines Agency (EMA) as a treatment for fungal diseases candidemia and invasive candidiasis. While CDTX has rights for rezafungin in Japan, the company has sold the U.S. commercial rights for the drug to Melinta Therapeutics and rights for all other territories to Mundipharma. Chief Executive Jeffrey Stein said that his company remains on track to receive up to ~$108M in milestone payments as additional non-dilutive capital from partners subject to the accomplishment of events scheduled for the next two years. Read more about the CDTX’s licensing deal for rezafungin with Melinta in the U.S.Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Cidara Therapeutics (NASDAQ:CDTX) said it began dosing in a phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of the antiviral against influenza virus. CD388 is aimed to deliver universal prevention of seasonal and pandemic influenza, the company said in A a Sept. 13 press release. Cidara said the study is being conducted under an exclusive worldwide license and collaboration with Johnson & Johnson (NYSE:JNJ), to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) to prevent seasonal and pandemic influenza. Multiple dose levels of CD388 will be evaluated in people who will receive a single administration of CD388 or placebo prior to influenza viral challenge. The trial is expected to enroll up to 168 healthy adults. "Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems. We look forward to announcing the findings next year, and continuing our collaboration with Janssen who will be spearheading late-stage development," said Cidara President and CEO Jeffrey Stein.Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09. Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$185m |
| Jun 30 2025 | n/a | n/a | -US$117m |
| Mar 31 2025 | n/a | n/a | -US$186m |
| Dec 31 2024 | US$6m | US$618k | -US$170m |
| Sep 30 2024 | n/a | n/a | -US$126m |
| Jun 30 2024 | n/a | n/a | -US$114m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | US$2m | US$594k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$22m |
| Dec 31 2022 | US$1m | US$566k | -US$22m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$2m | US$566k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | US$1m | US$542k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$1m | US$526k | -US$41m |
Compensazione vs Mercato: La retribuzione totale di Jeff ($USD 5.97M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.28M ).
Compensazione vs guadagni: La retribuzione di Jeff è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Jeff Stein (70 yo)
Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 12yrs | US$5.97m | 0.23% $ 16.2m | |
| Chief Scientific Officer | 4.5yrs | US$2.04m | 0.035% $ 2.5m | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| COO & Corporate Secretary | 4.4yrs | US$929.86k | 0.079% $ 5.5m | |
| Senior Vice President of People & Culture | 5yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 2.4yrs | Nessun dato | 0.066% $ 4.6m | |
| Chief Business Officer | 1.4yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development | less than a year | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di CDTX è considerato esperto (durata media dell'incarico 3.4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 12yrs | US$5.97m | 0.23% $ 16.2m | |
| Independent Chairman of the Board | 11.8yrs | US$451.51k | 0.00048% $ 33.5k | |
| Independent Director | 11.8yrs | US$423.51k | 0% $ 0 | |
| Independent Director | 5yrs | US$331.56k | 0.000050% $ 3.5k | |
| Independent Director | 5yrs | US$332.29k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$391.10k | 0.011% $ 734.9k | |
| Independent Director | 1.8yrs | US$85.52k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$88.26k | 0% $ 0 | |
| Director | 1yr | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CDTX sono considerati esperti (durata media dell'incarico 5 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/01/06 20:12 |
| Prezzo dell'azione a fine giornata | 2026/01/06 00:00 |
| Utili | 2025/09/30 |
| Utili annuali | 2024/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cidara Therapeutics, Inc. è coperta da 8 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Timothy Chiang | BTIG |
| Eun Kyung Yang | Jefferies LLC |
| Kevin DeGeeter | Ladenburg Thalmann & Company |